AR024735A1 - Composiciones estables de factor viii - Google Patents

Composiciones estables de factor viii

Info

Publication number
AR024735A1
AR024735A1 ARP000103610A ARP000103610A AR024735A1 AR 024735 A1 AR024735 A1 AR 024735A1 AR P000103610 A ARP000103610 A AR P000103610A AR P000103610 A ARP000103610 A AR P000103610A AR 024735 A1 AR024735 A1 AR 024735A1
Authority
AR
Argentina
Prior art keywords
ions
factor viii
stable factor
factor compositions
optionally
Prior art date
Application number
ARP000103610A
Other languages
English (en)
Original Assignee
Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR024735(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9902685A external-priority patent/SE9902685D0/xx
Priority claimed from SE0001743A external-priority patent/SE0001743D0/xx
Application filed by Biovitrum Ab Publ filed Critical Biovitrum Ab Publ
Publication of AR024735A1 publication Critical patent/AR024735A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

La presente invencion se relaciona con una composicion farmacéutica que comprende Factor VIII y los iones metálicos divalentes Zn2+ y Cu2+, optativamenteen presencia de iones de Ca2+ y/o iones de Mn2+, donde dicho Factor VIII es estable sin laadicio n de albumina. También se relaciona con un método para laproduccion de Factor VIII recombinante a partir de células de mamíferos portadoras del gen de dicho factor, que comprende el cultivo de dichas células demamíferos en un medio libre deproteínas derivadas de plasma y suplementado con iones de metales divalentes, incluyendo CU2+ y Zn2+, y optativamente enpresencia de iones Ca2+ y Mn2+.
ARP000103610A 1999-07-13 2000-07-13 Composiciones estables de factor viii AR024735A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9902685A SE9902685D0 (sv) 1999-07-13 1999-07-13 Stable protein compositions
US14682899P 1999-08-02 1999-08-02
SE0001743A SE0001743D0 (sv) 2000-05-11 2000-05-11 Stable protein compositions II

Publications (1)

Publication Number Publication Date
AR024735A1 true AR024735A1 (es) 2002-10-23

Family

ID=27354553

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103610A AR024735A1 (es) 1999-07-13 2000-07-13 Composiciones estables de factor viii

Country Status (14)

Country Link
US (1) US6599724B1 (es)
EP (1) EP1194161B1 (es)
JP (1) JP4674021B2 (es)
AR (1) AR024735A1 (es)
AT (1) ATE310533T1 (es)
AU (1) AU780415B2 (es)
CA (1) CA2378751C (es)
CY (1) CY1104986T1 (es)
DE (1) DE60024268T2 (es)
DK (1) DK1194161T3 (es)
ES (1) ES2252028T3 (es)
NO (1) NO330048B1 (es)
NZ (1) NZ516400A (es)
WO (1) WO2001003726A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2130554E (pt) 1999-02-22 2012-11-19 Univ Connecticut Formulações de factor viii isentas de albumina
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
RU2366451C2 (ru) 2002-06-21 2009-09-10 Ново Нордиск Хелт Кэр Аг Стабилизированные твердые композиции полипептидов фактора vii
KR100714584B1 (ko) † 2002-12-27 2007-05-07 니혼긴센기카이가부시키가이샤 유가증권의 광학적 특징 검출용 광학센서장치
KR20050110682A (ko) * 2003-03-18 2005-11-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
MXPA05012476A (es) * 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
JP4644663B2 (ja) * 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
ATE547114T1 (de) 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
EP1644030B1 (en) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CN1845753A (zh) 2003-08-14 2006-10-11 诺和诺德医疗保健公司 因子ⅶ多肽类的含水液体药物组合物
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
US20050090551A1 (en) * 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
EP1699469B1 (en) * 2003-12-03 2010-04-07 University of Rochester Recombinant factor viii having increased specific activity
BRPI0417721B8 (pt) * 2003-12-19 2021-05-25 Novo Nordisk Healthcare Ag kit contendo um medicamento farmacêutico, método para preparar uma formulação líquida de um fator recombinante viia, composição e métodos para preparar as composições
US7422875B2 (en) 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
EP1919498A2 (en) * 2005-08-26 2008-05-14 Maxygen Holdings Ltd. Liquid factor vii composition
FR2908892B1 (fr) * 2006-11-21 2009-02-20 Hyphen Biomed Soc Par Actions Procede pour le dosage chromogenique de l'activite du facteur viii:c et necessaire de dosage chromogenique de l'activite du facteur viii:c,dans les plasmas ou les fractions therapeutiques
US8183345B2 (en) 2007-11-01 2012-05-22 University Of Rochester Recombinant factor VIII having reduced inactivation by activated protein C
SG10201503304RA (en) 2007-12-27 2015-06-29 Baxter Int Cell culture processes
NZ593190A (en) * 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
AU2011323236B2 (en) 2010-11-05 2017-03-30 Takeda Pharmaceutical Company Limited A new variant of antihemophilic factor VIII having increased specific activity
US9115381B2 (en) * 2011-05-13 2015-08-25 Octapharma Ag Method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII
US9394353B2 (en) 2011-10-18 2016-07-19 Csl Limited Method for improving the stability of purified factor VIII after reconstitution
MX2016012869A (es) 2014-04-01 2017-05-12 Advantech Bioscience Farmacêutica Ltda Estabilizacion del factor viii sin calcio como un excipiente.
EP3126003A4 (en) * 2014-04-01 2017-11-29 Advantech Bioscience Farmacêutica Ltda. Stable factor viii formulations with low sugar-glycine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788944T2 (de) 1986-06-24 1994-05-26 Novo Nordisk As Verfahren zur herstellung eines koagulationsaktiven komplexes vom faktor viii-fragment.
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
AU7254894A (en) * 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
WO1998016629A1 (en) * 1996-10-11 1998-04-23 Life Technologies, Inc. Defined systems for epithelial cell culture and use thereof
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium

Also Published As

Publication number Publication date
AU780415B2 (en) 2005-03-17
JP2003504345A (ja) 2003-02-04
AU6193300A (en) 2001-01-30
NO20020120D0 (no) 2002-01-10
DE60024268D1 (de) 2005-12-29
NO20020120L (no) 2002-02-28
NZ516400A (en) 2004-02-27
ATE310533T1 (de) 2005-12-15
WO2001003726A1 (en) 2001-01-18
JP4674021B2 (ja) 2011-04-20
EP1194161A1 (en) 2002-04-10
ES2252028T3 (es) 2006-05-16
CA2378751C (en) 2012-11-06
EP1194161B1 (en) 2005-11-23
CY1104986T1 (el) 2009-11-04
CA2378751A1 (en) 2001-01-18
US6599724B1 (en) 2003-07-29
DE60024268T2 (de) 2006-08-03
NO330048B1 (no) 2011-02-07
DK1194161T3 (da) 2006-02-13

Similar Documents

Publication Publication Date Title
AR024735A1 (es) Composiciones estables de factor viii
ATE338118T1 (de) Neues peptid, apoep1.b, zusammensetzungen und verwendungen davon
NO20022359D0 (no) Inhibering av genekspresjon med dsRNA
BR0206521A (pt) Misturas de enzimas microbianas
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
CY1105772T1 (el) Συνθεσεις και μεθοδοι για βελτιωμενη κυτταρικη καλλιεργεια
DE60144145D1 (de) Subtilisin-variante
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
DK1650307T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer
TR200200129T2 (tr) Hepatit C inhibitörü tri-peptidler
WO2004070013A3 (en) Use of islet 1 as a marker for isolating or generating stem cells
BRPI0411475A (pt) adições de código genético de aminoácido reativo não natural
HK1080895A1 (en) Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
BR0208456A (pt) Métodos para cultura de circovìrus
BR0112643A (pt) Tioesterases de acil coenzima a
DE60134280D1 (de) In vitro rekonstituierte lagen des menschlichen ho
DK1276874T3 (da) Kloning og ekspression af en syreresistent ekstracellulær lipase fra yarrowia lipolytica
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
DE60230990D1 (de) Zellkulturmethode zur erzeugung von prostata-ähnlichen acini
AR025969A1 (es) Homologos de ifn-alfa
SE0302103L (sv) Xylanaser med förhöjd termofilicitet och alkalofilicitet
ATE397019T1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
AR030593A1 (es) Sistema tensioactivo
BR9711540A (pt) Inibidores de protease proteìnico estabilizados e variantes dos mesmos
DE60042700D1 (de) Integrin-vermittelte arzneimittel-zielrichtung

Legal Events

Date Code Title Description
FC Refusal